SILO Share Price Performance
US$0.60
-0.60 (-49.83%)
90.3% undervalued intrinsic discount
US$6.20
Fair Value
Price US$0.60
CMCVentures US$6.20
Fair ValueUS$6.20
Share PriceUS$0.60
90.3% undervalued intrinsic discount
Silo Pharma, Inc. Stock Price
- 1 Narratives written by author
- 6 Comments on narratives written by author
- 175 Fair Values set on narratives written by author
SILO Community Narratives
CM
Fair Value US$6.2 90.3% undervalued intrinsic discount
Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s
11users have liked this narrative
6users have commented on this narrative
98users have followed this narrative
Groundbreaking therapies that could change the treatment landscape for PTSD, fibromyalgia, MS & Alzheimer’s
Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.
11users have liked this narrative
6users have commented on this narrative
98users have followed this narrative
CM
US$6.2
90.3% undervalued intrinsic discount
CMCVentures Fair Value
Revenue growth
234% p.a.
Profit Margin
30%
Future PE
20x
Share price in 2029
US$10.8
Snowflake Analysis
Silo Pharma, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.37
- 91.90%
- -6,789.22%
- 0%
About SILO
- Founded
- 2010
- Employees
- 3
- CEO
- WebsiteView website
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
